KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Interest Expenses (2018 - 2025)

Vertex Pharmaceuticals (VRTX) has 10 years of Interest Expenses data on record, last reported at $3.3 million in Q4 2025.

  • For Q4 2025, Interest Expenses rose 17.86% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $13.3 million, down 56.54%, while the annual FY2025 figure was $13.3 million, 56.54% down from the prior year.
  • Interest Expenses reached $3.3 million in Q4 2025 per VRTX's latest filing, roughly flat from $3.3 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $11.2 million in Q2 2023 and bottomed at $2.8 million in Q4 2024.
  • Average Interest Expenses over 3 years is $6.6 million, with a median of $5.6 million recorded in 2024.
  • Peak YoY movement for Interest Expenses: tumbled 73.58% in 2024, then increased 17.86% in 2025.
  • A 3-year view of Interest Expenses shows it stood at $10.6 million in 2023, then crashed by 73.58% to $2.8 million in 2024, then grew by 17.86% to $3.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $3.3 million in Q4 2025, $3.3 million in Q3 2025, and $3.7 million in Q2 2025.